Non-coding RNAs in Regulating Tumor Angiogenesis

Song, Xin; Guo, Junming; Song, Peng; Duan, Dongzhu; Guo, Wenjing

doi:10.3389/fcell.2021.751578

Cited by 8 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, new advances have been made in exploring the regulatory role of ncRNAs in tumor angiogenesis. For example, RNA sponges, specific interfering molecules targeting ncRNAs that are proto-oncogenes, were synthesized for anti-tumor angiogenesis therapy [ 40 ]. In conclusion, ncRNAs such as miR-199a, which regulate tumor angiogenesis, could be a target for the development of new drugs for the treatment of cancer.…”

Section: Resultsmentioning

confidence: 99%

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

Wei

Chai

et al. 2022

IJMS

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death worldwide. miR-199a, which has two mature molecules: miR-199a-3p and miR-199a-5p, plays an important biological role in the genesis and development of tumors. We collected recent research results on lung cancer and miR-199a from Google Scholar and PubMed databases. The biological functions of miR-199a in lung cancer are reviewed in detail, and its potential roles in lung cancer diagnosis and treatment are discussed. With miR-199a as the core point and a divergence outward, the interplay between miR-199a and other ncRNAs is reviewed, and a regulatory network covering various cancers is depicted, which can help us to better understand the mechanism of cancer occurrence and provide a means for developing novel therapeutic strategies. In addition, the current methods of diagnosis and treatment of lung cancer are reviewed. Finally, a conclusion was drawn: miR-199a inhibits the development of lung cancer, especially by inhibiting the proliferation, infiltration, and migration of lung cancer cells, inhibiting tumor angiogenesis, increasing the apoptosis of lung cancer cells, and affecting the drug resistance of lung cancer cells. This review aims to provide new insights into lung cancer therapy and prevention.

show abstract

Section: Resultsmentioning

confidence: 99%

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

Wei

Chai

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The administration of ncRNAs has emerged as a potential therapeutic strategy to stop tumor progression through angiogenesis suppression [101]. MiR-29b is a tumor suppressor miRNA in many cancers, where it regulates cell proliferation, apoptosis, and differentiation, and its expression also decreases in breast cancer tissue compared with normal mammary tissue [65].…”

Section: Non-coding Rnas In the Regulation Of Tam-induced Angiogenesismentioning

confidence: 99%

Non-Coding RNAs in the Crosstalk between Breast Cancer Cells and Tumor-Associated Macrophages

Benedetti

Turco

Fontemaggi

et al. 2022

ncRNA

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) play a pivotal role in regulating the tumor microenvironment (TME) by controlling gene expression at multiple levels. In tumors, ncRNAs can mediate the crosstalk between cancer cells and other cells in the TME, such as immune cells, stromal cells, and endothelial cells, influencing tumor development and progression. Tumor-associated macrophages (TAMs) are among the most abundant inflammatory cells infiltrating solid cancers that promote tumorigenesis, and their infiltration correlates with a poor prognosis in many tumors. Cancer cells produce different ncRNAs that orchestrate TAM recruitment and polarization toward a tumor-promoting phenotype. Tumor-reprogrammed macrophages shape the TME by promoting angiogenesis and tissue remodeling, and suppressing the anti-tumor activity of adaptive immune cells. TAMs can also produce ncRNA molecules that boost cancer cell proliferation and direct their phenotype and metabolic changes facilitating cancer progression and metastasis. This review will focus on the crosstalk between cancer cells and TAMs mediated by microRNAs and long non-coding RNAs during breast cancer (BC) initiation and progression.

show abstract

“…ncRNAs are functional RNA molecules that are not being translated into proteins but are involved in various physiological and pathological processes. 21 It was found that the dysregulation of certain ncRNAs is related to tumorigenesis, neurological, cardiovascular development, and other diseases. 22 In recent decades, a large number of studies have reported the key role of ncRNAs in cancer progression, metastasis, and drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

et al. 2022

View full text Add to dashboard Cite

Ovarian cancer (OC) is the third most common gynecological malignancy with the highest mortality worldwide. OC is usually diagnosed at an advanced stage, and the standard treatment is surgery combined with platinum or paclitaxel chemotherapy. However, chemoresistance inevitably appears coupled with the easy recurrence and poor prognosis. Thus, early diagnosis, predicting prognosis, and reducing chemoresistance are of great significance for controlling the progression and improving treatment effects of OC. Recently, much insight has been gained into the non-coding RNA (ncRNA) that is employed for RNAs but does not encode a protein, and many types of ncRNAs have been characterized including long-chain non-coding RNAs, microRNAs, and circular RNAs. Accumulating evidence indicates these ncRNAs play very active roles in OC progression and metastasis. In this review, we briefly discuss the ncRNAs as biomarkers for OC prognosis. We focus on the recent advances of ncRNAs as therapeutic targets in preventing OC metastasis, chemoresistance, immune escape, and metabolism. The novel strategies for ncRNAs-targeted therapy are also exploited for improving the survival of OC patients.

show abstract

Non-coding RNAs in Regulating Tumor Angiogenesis

Cited by 8 publications

References 99 publications

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

Non-Coding RNAs in the Crosstalk between Breast Cancer Cells and Tumor-Associated Macrophages

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

Contact Info

Product

Resources

About